Expiration | Code | ||
---|---|---|---|
aflibercept, Eylea, Regeneron Pharmaceuticals, Inc. | |||
2030-02-08 | Orphan excl. |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | 1 | — | — | 1 |
Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Aflibercept |
INN | aflibercept |
Description | Aflibercept (immunoadhesin) |
Classification | Protein |
Drug class | receptor molecules or membrane ligands, natural, modified or modified: vascular endothelial growth factor (VEGF) receptors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1742982 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB08885 |
UNII ID | 15C2VL427D (ChemIDplus, GSRS) |